|
If you’ve been looking for a source for independent and insightful research that speak plain English, look no more.
Each month the Wong’s BioTech Stock Report provides a fresh, intuitive, inside look at the science and business of biotech investing. Our report takes you behind the canned quotes from press releases, beyond the momentum-driven stock analysts, and past the hype of mainstream stock-touters. The BioTech Stock Report gets to the core of what makes biotechnology companies tick: Science and Innovation.
The Wong’s BioTech Stock Report is the only biotech newsletter that explains recent developments in light of underlying technology. The BioTech Stock Report looks beyond short-term successes and setbacks because we know that in the long run good technology wins the biotech game.
Our report is an “information integrator” specializing in biotechnology stocks. We bring together the mass of medical scientific data that is available and interpret it for you in a sixteen-page report that is published 12 times a year. The report is divided into four key parts.
An industry analysis with detailed rationale explaining the technology, examining new products, evaluating their potential, the markets and the likely impact it has on a company’s future. We usually discuss either a specific industry segment or talk about important industry-wide issues. This section provides useful background information and helps subscribers evaluate breaking news while building a information base.
The current recommendation section provides analysis of up and coming company in the biotechnology sector. Here you will find easy to understand information and exciting new opportunities in the biotechnology sector. We typically look for stocks with the potential to grow.
In our BioPortfolio, we also focus on companies with more than one product in development. Your best bet is a mix of Phase III and Phase II products, rather than one that may be little more than hype. In this section, the companies are broken down by the amount of risk that is in general risk increases as market cap decreases.
Since we are independent and unbiased, the BioTech Stock Report gives the reader the facts!
|
